Akebia Therapeutics Inc (AKBA)
1.845
+0.16
(+9.17%)
USD |
NASDAQ |
Nov 04, 16:00
1.85
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Debt to Equity Ratio: -1.127 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | -1.127 |
| March 31, 2024 | -1.106 |
| December 31, 2023 | -1.134 |
| September 30, 2023 | -1.081 |
| June 30, 2023 | -1.585 |
| March 31, 2023 | -3.504 |
| December 31, 2022 | 12.63 |
| September 30, 2022 | 4.760 |
| June 30, 2022 | 1.576 |
| March 31, 2022 | 3.747 |
| December 31, 2021 | 1.318 |
| September 30, 2021 | 0.7089 |
| June 30, 2021 | 0.555 |
| March 31, 2021 | 0.4517 |
| December 31, 2020 | 0.3892 |
| September 30, 2020 | 0.2409 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.2062 |
| March 31, 2020 | 0.1919 |
| December 31, 2019 | 0.192 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.0236 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.504
Minimum
Mar 2023
12.63
Maximum
Dec 2022
0.9176
Average
0.2409
Median
Sep 2020
Debt to Equity Ratio Benchmarks
| Corcept Therapeutics Inc | 0.00 |
| Bioventus Inc | 2.539 |
| Eli Lilly and Co | 2.185 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Palatin Technologies Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 220.20M |
| Total Liabilities (Quarterly) | 253.95M |
| Shareholders Equity (Quarterly) | -33.75M |
| Current Ratio | 1.045 |
| Net Debt Paydown Yield | 1.15% |